Dian Diagnostics sees mixed Q3 2025: revenue and profit down, cash flow up

Dian Diagnostics Group reported total operating income of yuan 7.57 bn for the first nine months of 2025, an 18.28% decrease year-over-year. Net profit attributable to shareholders declined by 56.67% to yuan 56.7m, with diluted earnings per share at yuan 0.0928, down 56.19%. The company also noted a 13.52% decrease in quarterly operating income to yuan 2.63 bn.

Despite these declines, cash flow from operating activities surged by 1508.33% to yuan 871.7m for the first nine months, attributed to improved cost control and reduced cash outflow relative to inflow. The company highlighted strategic progress, including expanding its precision centers, acquiring new customers, and advancing AI products, which contributed to its operational stability.

The board of directors approved the third-quarter report on October 22, 2025. The full report was published on October 24, 2025, on the Shenzhen Stock Exchange’s GEM information disclosure website.